ESMO 2018 | Standard of care and progress with PARP inhibitors for ovarian cancer

Susana Banerjee

Susana Banerjee, MBBS, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, speaks at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, about the standard of care and progress with PARP inhibitors for ovarian cancer.

Share this video